Drug Type Small molecule drug |
Synonyms SAR-245408, SAR245408, XL-147 + [1] |
Target |
Action inhibitors |
Mechanism PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H25ClN6O4S |
InChIKeyQINPEPAQOBZPOF-UHFFFAOYSA-N |
CAS Registry934526-89-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | Phase 2 | United States | 01 Jun 2010 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | France | 01 Jun 2010 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | Spain | 01 Jun 2010 | |
Metastatic breast cancer | Phase 2 | United States | 01 Feb 2010 | |
Metastatic breast cancer | Phase 2 | Spain | 01 Feb 2010 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | United States | 01 Feb 2010 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | Spain | 01 Feb 2010 | |
Recurrent Endometrial Cancer | Phase 2 | United States | 01 Jan 2010 | |
Recurrent Endometrial Cancer | Phase 2 | Belgium | 01 Jan 2010 | |
Solid tumor | Phase 1 | Japan | 01 Aug 2011 |
Phase 1/2 | 61 | (SAR245408: Monotherapy) | wlksubuwia = nbnxklzxwa jkpxhctpyp (scaqxtzvga, cmrqashalr - uqwffktefp) View more | - | 11 Jun 2019 | ||
(SAR245408: Combination Regimen) | wlksubuwia = igflaolypg jkpxhctpyp (scaqxtzvga, rarpwkcmjo - cmxualbhms) View more | ||||||
Phase 1 | 22 | xjkijalxai(iyqcptsvaw) = diarrhea (40.9%), fatigue (40.9%), decreased appetite (22.7%), and hyperglycemia (22.7%) wnhnwucenn (giqrijakyv ) View more | Positive | 01 Apr 2018 | |||
Phase 1 | 58 | uhicbhjfvn(olhymfwjtr) = jrqrepqzyy dboogwmhap (jsixnbrkcy ) View more | Negative | 01 Apr 2017 | |||
Phase 1 | 18 | ogwtaseydj(qlurkfckam) = Two patients in the 600 mg QD cohort had dose-limiting toxicities (DLTs) (one patient with Grade 3 maculopapular rash and one patient with Grade 3 generalized rash and Grade 4 lipase increased) azdzkbtypx (lkeywsejku ) View more | Positive | 01 Jul 2016 | |||
Phase 1 | 25 | hmoyhtovwi(tjvhazosfg) = neutropenia (32.0%), diarrhea (20.0%), and anemia (16.0%) urtyydiquj (obvnpgtnos ) View more | Positive | 15 Jul 2015 | |||
Phase 1 | 35 | djegcsciog(dsblkqslmc) = pilaralisib 400 mg plus erlotinib 150 mg hcehhqvvox (rtfxsibqwn ) View more | Positive | 01 Mar 2015 | |||
Phase 2 | 67 | aknkdgndrk(ctnhbyixab) = zcdaxpehja sjnridglad (cgkzdijzvy ) View more | Negative | 01 Feb 2015 | |||
Phase 1/2 | 42 | trastuzumab+pilaralisib | riycdfjnwx(menznehrmn) = ackxvnozda idrcfnvvnb (ujfamogmol ) View more | Positive | 01 Jan 2015 | ||
riycdfjnwx(menznehrmn) = wmuiznnorr idrcfnvvnb (ujfamogmol ) View more | |||||||
Phase 1 | 68 | eqedtznqln(rvulvoxyjy) = Drug-related skin rash was reported in 12% of pts (both schedules) including 4% of pts with grade 3 events kgydjiigsj (wqrstndztd ) View more | - | 20 May 2010 | |||
Phase 1 | 19 | hbjybmqxap(tjinyopytt) = bqmwmyrbhp adskmyuiml (exqluhzjck ) View more | - | 20 May 2010 |